Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700630 | 0.90 | SLC6A4 (0.42) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3953009 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3952205 | 0.76 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27662381 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3986431 | 0.75 | SLC6A4 (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27662471 | 0.70 | SLC6A2 (0.39) | SLC6A2 | |
| SCHEMBL3973723 | 0.67 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL3974898 | 0.67 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL4494226 | 0.67 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3950407 | 0.67 | STS (0.45) | MEN1KMT2AGRM5LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1894226-A | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH CORP (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1687288-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1678154-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1673059-A2 | ALKANOL AND CYCLOALKANOL-AMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1673084-A1 | 1-2' (1,4'-BIPERIDIN-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1673090-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |